AU2001288271A1 - Methods for treating inflammatory diseases - Google Patents

Methods for treating inflammatory diseases

Info

Publication number
AU2001288271A1
AU2001288271A1 AU2001288271A AU8827101A AU2001288271A1 AU 2001288271 A1 AU2001288271 A1 AU 2001288271A1 AU 2001288271 A AU2001288271 A AU 2001288271A AU 8827101 A AU8827101 A AU 8827101A AU 2001288271 A1 AU2001288271 A1 AU 2001288271A1
Authority
AU
Australia
Prior art keywords
methods
inflammatory diseases
treating inflammatory
treating
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288271A
Inventor
Harrihar A. Pershadsingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001288271A1 publication Critical patent/AU2001288271A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001288271A 2000-08-17 2001-08-16 Methods for treating inflammatory diseases Abandoned AU2001288271A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22590700P 2000-08-17 2000-08-17
US60225907 2000-08-17
US23050900P 2000-09-06 2000-09-06
US60230509 2000-09-06
PCT/US2001/025668 WO2002013812A1 (en) 2000-08-17 2001-08-16 Methods for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
AU2001288271A1 true AU2001288271A1 (en) 2002-02-25

Family

ID=26920030

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288271A Abandoned AU2001288271A1 (en) 2000-08-17 2001-08-16 Methods for treating inflammatory diseases

Country Status (2)

Country Link
AU (1) AU2001288271A1 (en)
WO (1) WO2002013812A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441941A1 (en) * 2001-04-06 2002-10-17 F. Hoffmann-La Roche Ag Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
US20040198774A1 (en) * 2001-08-23 2004-10-07 Shinichi Ishii Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
EP1465622A1 (en) * 2001-11-26 2004-10-13 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
JP2005511713A (en) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア Treatment for age-related macular degeneration
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
CA2482789A1 (en) * 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treatglaucomatous retinopathies/optic neuropathies
US20030220300A1 (en) * 2002-05-14 2003-11-27 Hwang Cheng Shine Reduction of hair growth
MXPA05003063A (en) * 2002-09-20 2005-05-27 Alcon Inc Use of cytokine synthesis inhibitors for the treatment of dry eye disorders.
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
EP1637161A4 (en) * 2003-04-22 2007-06-27 Astellas Pharma Inc REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPAR [delta] AGONIST
MXPA06011218A (en) * 2004-04-01 2007-01-16 Aventis Pharma Inc Use of ppr delta agonists for treating demyelinating diseases.
JP2005350451A (en) * 2004-05-11 2005-12-22 Santen Pharmaceut Co Ltd Agent for treating keratoconjunctival trouble
CA2566098A1 (en) * 2004-05-11 2005-11-17 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctival disorder
WO2006010504A1 (en) * 2004-07-29 2006-02-02 Werner Bollag Rxr antagonist treatment against multiple sclerosis
FR2897534A1 (en) * 2006-02-17 2007-08-24 Galderma Res & Dev USE OF TESAGLITAZAR FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
KR101508020B1 (en) * 2007-05-21 2015-04-06 센주 세이야꾸 가부시키가이샤 Pharmaceutical containing pparδ agonist
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
GB0913672D0 (en) 2009-08-05 2009-09-16 Argenta Discovery Ltd Glitazones
PL2222272T3 (en) * 2008-08-07 2013-04-30 Pulmagen Therapeutics Inflammation Ltd Respiratory disease treatment
DK2379507T3 (en) 2008-12-30 2014-01-27 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
CN102573837A (en) * 2009-07-30 2012-07-11 艾斯特司治疗有限公司 Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma
WO2011084824A1 (en) * 2009-12-21 2011-07-14 Sarah Bacus Compositions and methods for increasing cellular fat and bleaching skin
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201805554D0 (en) * 2018-04-04 2018-05-16 Wren Therapeutics Therapy for protein misfolding disease
US20210145802A1 (en) * 2018-04-04 2021-05-20 Wren Therapeutics Limited Therapy for ophthalmological conditions
CN112367971A (en) 2018-06-11 2021-02-12 加利福尼亚大学董事会 Demethylation for the treatment of ocular diseases
WO2024040256A2 (en) * 2022-08-19 2024-02-22 National Health Research Institutes Pharmaceutical combinations and methods for preventing or treating neurodegenerative diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981586A (en) * 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
US6034110A (en) * 1998-01-12 2000-03-07 Allergan Sales, Inc. Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid and a PPARγ ligand

Also Published As

Publication number Publication date
WO2002013812A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
AU2001288271A1 (en) Methods for treating inflammatory diseases
IL155093A0 (en) Morpholin-acetamide derivatives for the treatment on inflammatory diseases
WO2002030487A8 (en) Methods for treating aneurysms
AU1294401A (en) Methods for treating fibroproliferative diseases
AU2002215125A1 (en) Well treatment method
AU2002224417A1 (en) Methods for treating il-18 mediated disorders
AU2002223827A1 (en) Well treatment
AU2001227966A1 (en) Methods for treating tumors
AU2001290685A1 (en) Methods for inhibiting inflammatory disease
AU2002232919A1 (en) Method for treating fibrotic diseases or other indications
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU2001237939A1 (en) Methods for treating glaucoma
AU2001227972A1 (en) Methods to treat alpha-1-antitrypsin deficiency
AU2001227953A1 (en) Methods for raising rabbits
EP1450820A4 (en) Method for treating or preventing inflammatory diseases
AU2002214487A1 (en) Method for inducing apoptiosis
AU4515001A (en) Compositions and methods for locally treating inflammatory diseases
IL155769A0 (en) Method for the treatment of inflammation
AU2002326991A1 (en) Methods for treating multiple sclerosis
AU2001266176A1 (en) Methods
AU2001238288A1 (en) Method and compositions for treating fibrotic diseases
AU2001250536A1 (en) Methods
AU2001267769A1 (en) Process